Cargando…
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
The significance of sclerostin for bone and cardiovascular health in patients with chronic kidney disease (CKD) is complex and incompletely understood. Experimental evidence suggests that anti-sclerostin therapy shows diminished efficacy on bone in the setting of CKD. Limited clinical evidence sugge...
Autor principal: | Cejka, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624769/ https://www.ncbi.nlm.nih.gov/pubmed/34822428 http://dx.doi.org/10.3390/metabo11110770 |
Ejemplares similares
-
Sclerostin and Cardiovascular Disease
por: Tobias, Jonathan H.
Publicado: (2023) -
Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
por: Fabre, Stéphanie, et al.
Publicado: (2020) -
Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
por: van Dinther, Maarten, et al.
Publicado: (2013) -
Sclerostin
por: Silverman, Stuart L.
Publicado: (2010) -
The Role of Sclerostin in Bone Diseases
por: Vasiliadis, Elias S., et al.
Publicado: (2022)